Browse existing research summaries on rapamycin and longevity science.
In a 13-week randomised trial in 40 sedentary adults aged 65 to 85, once-weekly sirolimus 6 mg added to a home exercise programme did not improve chair-stand performance, and the sensitivity analyses suggested it modestly blunted training gains.
A preprint comparing 14 DNA methylation clocks in about 1,000 older adults from the Berlin Aging Study II finds that the DunedinPACE clock tracks cognitive performance and decline most consistently.
A single-arm, open-label pilot trial in 14 people with early Alzheimer's disease: six months of weekly oral rapamycin was tolerated, but glucose metabolism in the pre-specified brain regions did not change.
An open-label phase 1 pilot trial in ten older adults with mild cognitive impairment or early Alzheimer's dementia: eight weeks of low-dose rapamycin was tolerated without serious events, but the drug was not detectable in cerebrospinal fluid and cognition did not change.
A clinical review of geroscience: which ageing pathways can be modified, and how much human evidence currently supports each intervention.
A conference abstract reporting that four weeks of low-dose sirolimus in two cognitively normal middle-aged women carrying APOE4 was followed by higher brain blood flow on MRI.
The published protocol for RAPA-EX-01: a 40-person randomised trial asking whether once-weekly sirolimus 6 mg preserves or blunts the strength and endurance gains of a 13-week home exercise programme in adults aged 65 to 85.
A systematic review of 33 human biological clocks compares how well methylation-based and clinical-biomarker clocks predict chronological age and mortality, and reports that phenotypic clocks currently predict death better than epigenetic ones.
A phase 2a randomised, placebo-controlled trial in 264 adults aged 65 and over reports that six weeks of a low-dose two-drug mTOR inhibitor regimen was associated with fewer self-reported infections over the following year and an improved antibody response to influenza vaccination.
An Oncotarget editorial arguing that because neurovascular deficits appear in APOE4 carriers before amyloid and tau, reversing them with mTOR inhibition could be a route to preventing Alzheimer's disease.
A randomised, observer-blind, placebo-controlled trial in 218 adults aged 65 and over reports that six weeks of low-dose RAD001 improved the antibody response to influenza vaccination and lowered PD-1-positive T cells.
Reviews mTOR inhibition and mammalian longevity, arguing the current evidence best fits lifespan extension mainly through cancer suppression, with symptomatic effects on some ageing traits.
